Study Type: POEM Purpose: Does rofecoxib reduce the risk of recurrent adenomatous polyps among patients with a history of colorectal ademomas? This evidencebased study sheet reports the cardiovascular finding from the study. Study justification: COX-2 is expressed at sites of inflammation like atheromatous plaques and neoplasms. COX-2 inhibition increases the risk of cardiovascular disease by reducing prostacyclin levels, increasing blood pressure, decreasing angiogenesis, and destabilizing plaque. Study Duration: 3 years (study was stopped 2 months early), n = 2586 Trial Design: double-blinded, randomized; placebo-controlled, multicenter (108 centers in 29 countries), 6-week placebo run-in to assess compliance (those with 80% were randomized), adverse events were adjudicated and reviewed by a blinded committee. Medication: rofecoxib 25 mg daily versus placebo Patients: 59 years (range 40 to ~90); 62% male; 84% white, 16% on low dose aspirin, 30% on antihypertensives, ~30% at risk for cardiovascular event, ~9% have symptomatic CV disease, 22% smoke History: ~30% cardiovascular disease, 36% hypertension, ~29% hyperlipidemia, 9% diabetes Inclusion: male and female; at least one large-bowel adenoma removed within 12 weeks before study, those not needing long-term aspirin or NSAID therapy, VIGOR trial caused investigators to allow low-dose aspirin (this was capped at 20% because it can be chemoprotective) Exclusion: uncontrolled hypertension (>165/95), angina, heart failure, MI, coronary angioplasty, CABG within a year, stroke or TIA within 2 years * there were no significant interactions between treatment groups and subgroups like aspirin use, age, diabetes, etc. *
1.
Are 
3.
Will the results help me? * more patients in the rofecoxib group was taking an antihypertensive during the trial (44% vs 36%), clopidogrel (4% vs 2%) * patients taking rofecoxib stopped treatment more due to cardiovascular events (HTN -32 vs 7; peripheral edema -7 vs 1)
